SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.53+4.5%Nov 25 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (8260)5/5/2003 11:07:10 PM
From: Biomaven  Read Replies (2) of 52153
 
However, the main question is why drug does not work well in synergy with chemo for early stage NSCLC, while all indicators (from drug action, and early data) suggest that it should?

This is still a total mystery to me. If not a synergistic effect, you would at least expect additive effect. They couldn't even find a subgroup where it worked well. This is one negative result that deserves a thorough article analyzing it.

I guess attention will now shift to Tarceva. This class of drugs is puzzling enough so that I really don't know what to expect.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News